At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORPH Orphazyme A/S
Not Yet Opened 04-01 16:00:00 EDT
0.8700
+0.0000
0.00%
High0.8700
Low0.8700
Vol0.00
Open0.8700
D1 Closing0.8700
Amplitude0.00%
Mkt Cap30.72M
Tradable Cap24.90M
Total Shares35.31M
T/O0.00
T/O Rate0.00%
Tradable Shares28.62M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Open Orphan Appoints Stephen Pinkerton as CFO & Executive Director
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.